Cell therapy through the use of nano-vesicles aims for colossal results. These nano-vesicles also known as exosomes, are produced by cells as faithful messengers for cell communication but also possess the potential of an efficient carrier for drug delivery. Exosomes have gained an important momentum by integrating into the fields of liquid biopsy, precision medicine and regenerative medicine. Cell-free therapy based on exosomes is witnessing a surge of published scientific papers, a rise of IP and registered clinicals trials, all driven by a swelling avidity among investors to support this transformative nanomedicine approach.
For cell-free treatment to become a reality, they need to overcome the many manufacturing hurdles posed by the large-scale production of purified exosomes. The exosomes market is identified as highly competitive without dominant players owing to many players operating in the market with a portfolio of technology still in R&D stages. The technology involved in manufacture of large-scale clinical-grade is a focal point for the market.
Unquestionably, the culture medium used with the parental cells plays a key role in the exosome secretion yield and content. An essential requisite is the use of a serum-, xeno-, and blood-free medium to meet the regulatory requirements of clinical-grade sEV's production.
Cells for Cells, a clinical-stage biotech company, has announced the publication of new data of its OxiumTMEXO cell culture media for increased exosome production in Frontiers in Biotechnology and Bioengineering, a specialized journal of the field. The company is part of REGENERO, the Chilean consortium for regenerative medicine supported by state funding (CORFO). In a head-to-head comparison, OxiumTMEXO outmatched the standard DMEM (starvation protocol) and a commercially available medium for exosome production. OxiumTMEXO allowed different type of cells, including the broadly used mesenchymal stem cells, to increase by 3-folds their particle production. The isolated exosomes expressed the typical pan markers while preserving their functionality both in vitro and in vivo.
"OxiumTMEXO unlocks the upstream manufacturing bottleneck of exosome production. By reducing production time and cost by half, this could bring exosome therapy one step forward on the translational track," comments Dr. Maroun Khoury, Chief Scientific Officer at Cells for Cells and REGENERO. Yet, other bioprocess hurdles are still to be bypassed, including the inefficient purification of clinical-grade exosomes, a problem that is currently being tackled by different companies through novel isolation platforms.
The cells tested in the published work correspond to mesenchymal stem/stromal cells from different tissue origins. Fibroblasts were also used as a non-stem cell type. Interestingly, OxiumTMEXO allowed a higher particle production independently of the cell type and tissue origin. Transmission electron microscopy image of isolated exosomes produced in Oxium™EXO, showing presence of cup-shaped vesicles below 200nm (Cells for Cells S.A).
"We observed a very low donor and batch variation of the secretion pattern. This offers an attractive alternative for GMP-compliant and scalable exosome production," says Dr. Francisca Alcayaga, principal investigator at Cells for Cells-REGENERO. The reproducibility and accuracy of OxiumTMEXO results were corroborated through additional testing by 3 independent and international laboratories. Cells for Cells is looking forward to partner with other biotech and industrials interested in the OxiumTMEXO technology.
Figueroa-Valdés A.I., de la Fuente C. et al. (2021). A chemically defined, xeno- and blood-free culture medium sustains increased production of small extracellular vesicles from mesenchymal stem cells. Front. Bioeng. Biotechnol. 2021;9:619930. doi: 10.3389/fbioe.2021.619930
OxiumTMEXO is a chemically-defined cell culture medium, free of xeno- and blood-derived components, that does not require serum or human platelet lysate supplementation for cell growth and maintenance during the exosome production cycle. Moreover, after 6 days of exosome production without the need of medium supplementation, the MSC's phenotype remained unchanged and a higher viability was achieved in comparison to conventional culture conditions.
About Cells for Cells S.A. Cells for Cells is a clinical-stage biotech company dedicated to the research, development and commercialization of cell therapies and tissue-engineered solutions. Cells for Cells counts with a broad biotechnological portfolio including Cellistem®OA and Cellistem®IC, a clinical trial-supported stem cell therapy for the treatment of knee osteoarthritis and heart failure; Inkure®, a bioink for high resolution 3D bioprinting; OxiumTMEXO, a culture media for the production of exosomes; and Veintis™, a bioinspired tissue-engineered vascular graft for vascular bypass applications, among others.
For further information please contact Cells for Cells at: email@example.com
Source: Cells for Cells